Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK | Subject: Cancer Research UK
Edited by the Laboratorytalk Editorial
Team on 29 June 2004
Another step closer to cracking cancer
The origin of a cancer which is common in people with HIV or who have had an organ transplant, Kaposi sarcoma, points way to possible future therapy
A virus turns lymph vessel cells into a cancer that affects people with weakened immune systems, according to research published today (29 June 2004) in Nature Genetics A Cancer Research UK team based at University College London has discovered that Kaposi sarcoma - which is common in people who are HIV positive or have had an organ transplant - first develops in the inner cell lining of lymph vessels, the transport network for the body's immune system
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Blocking gene opens doors to treat prostate cancer
Cancer Research UK scientists in Oxford have found a new way to make prostate cancer succumb more readily to currently used treatments
The findings indicate that drugs arresting the development of cells lining lymph vessels could prove powerful against Kaposi sarcoma.
They could also yield a test for doctors to predict which patients are likely to develop this cancer.
Kaposi sarcoma typically appears as coloured lesions or blotches on the skin, although it can spread to internal organs.
Further reading
Smarter approach to lung cancer
Cancer Research UK launches a major new clinical trial for the most common form of lung cancer, to test the effectiveness of one of the new generation of 'smart' cancer drugs
Major efforts needed against the big four killers
Comment from Cancer Research UK in response to press release from IARC/Annals of Oncology: "New European cancer figures for 2004 - cancer experts say major efforts needed against the big four killers"
Extension of the anastrozole (Arimidex) licence
Statement from Cancer Research UK on the extension of the anastrozole (Arimidex) licence says the drug is effective at preventing recurrence of breast cancer
The sarcoma is the most common cancer in individuals with HIV or Aids and for that reason is the most common cancer in many sub-Saharan African countries.
It is also one of the most common cancers in patients who have had their immune system suppressed to lower the likelihood that their bodies will reject a transplanted organ.
Professor Boshoff, who is joint director of the Cancer Research UK viral oncology group at UCL, says: "The cell type in which Kaposi sarcoma first develops has been a mystery since it was discovered in 1872.
"We analysed the genetic makeup of Kaposi sarcoma cells and found they are most similar genetically to cells of the inner lining of lymph vessels, known as lymphatic endothelial cells".
The research was funded by Cancer Research UK, with additional funding from the Medical Research Council and the Wellcome Trust.
The team also found that the virus that causes Kaposi sarcoma - the Kaposi sarcoma herpes virus (KSHV) - can turn the endothelial cells that line blood vessels into cancerous lymphatic endothelial cells.
Professor Boshoff adds: "We have shown for the first time that a virus can genetically reprogramme blood vessel endothelial cells into lymphatic endothelial cells, and that it is these lymphatic cells that develop into Kaposi sarcoma.
"Now that we know in which type of cell Kaposi sarcoma originates, we should be able to identify new ways to treat the condition.
"The findings could also yield new clues about other cancers that are triggered by viruses, such as cervical cancer".
The new study suggests that drugs inhibiting the growth of the lymphatic endothelium could prove a successful new way of combating Kaposi sarcoma.
Such drugs are already being developed.
The research also points towards a new predictive test for Kaposi sarcoma.
The team found that high levels of circulating growth factors which encourage lymphatic endothelial cells to proliferate were strongly associated with the development of Kaposi sarcoma.
Professor Boshoff adds: "Finding new cancers early is vital if treatment is to be successful.
"By testing blood for growth factors that encourage the cells lining lymph vessels to grow, doctors might be able to predict which high-risk patients - such as those with HIV or who have had an organ transplant - will subsequently develop Kaposi sarcoma".
Professor Robert Souhami, director of clinical and external affairs at Cancer Research UK, says: "People with HIV or who are taking immunosuppressive drugs are particularly susceptible to cancer.
"Chris Boshoff and his team's discovery that Kaposi sarcoma originates in the cellular lining of lymph vessels furthers our understanding of the disease and also has strong therapeutic implications.
"This is a good example of how research into the basic workings of cells and viruses can open new avenues of opportunity for treatment." Nature Genetics 2004 Volume 36 (7).
Kaposi sarcoma causes tumours to develop in the tissues below the skin surface, or in the mucous membranes of the mouth or nose.
The lesions appear as raised blotches or nodules that may be purple, brown or red in colour.
Whereas most cancers begin in one place in the body and may then spread around the body, Kaposi sarcoma can appear in several parts of the body at the same time.
Kaposi sarcoma commonly disappears if the immune system is restored.
It can otherwise lead to potentially fatal intestinal and lung lesions.
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
